{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:36:07Z","timestamp":1787236567896,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a multi-organ autoimmune disease that commonly affects the gastrointestinal tract, but can also affect other organs throughout the body. Less is known, however, about kidney involvement in IBD. Although IBD has been associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), these results have been inconsistent. The present study analyzed the prevalence of concurrent CKD and ESRD in patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Cochrane, Web of Science, and Embase were searched for studies published through October 2023 on IBD patients with concurrent CKD or ESRD. Outcomes included the incidence rates and odds ratios (OR) of concurrent CKD and ESRD in IBD patients. The quality of included studies was assessed using the Newcastle-Ottawa Scale, and sequential sensitivity was analyzed. Publication bias was evaluated using Egger\u2019s test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine studies were included in this meta-analysis. The combined results of eight studies, which included 239,042 IBD patients, showed that the prevalence of CKD in IBD patients was 5% (95% confidence interval [CI]: 1\u20139%). The combined results of two studies, which included 40,341 IBD patients, showed that the prevalence of ESRD in IBD patients was 0.2% (95% CI: \u22120.08\u20130.12%). The combined results of six case\u2013control studies reported that the risk of CKD was significantly higher in patients with than without IBD (OR 1.36, 95% CI: 1.08\u20131.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although studies have shown an increased risk of CKD in IBD, due to the small number of included studies and high heterogeneity across studies, it is not enough to definitively conclude that CKD is more common in patients with IBD. But patients with IBD should be regularly monitored for CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1485087","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:37:11Z","timestamp":1727915831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Concurrent chronic kidney disease in patients with inflammatory bowel disease, a systematic review and meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaoping","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sileng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00535-022-01903-6","article-title":"Renal manifestations in inflammatory bowel disease: a systematic review","volume":"57","author":"van Hoeve","year":"2022","journal-title":"J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201506020","article-title":"Chronic kidney disease","volume":"162","author":"Drawz","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ekir.2023.11.011","article-title":"Kidney diseases associated with inflammatory bowel disease: impact of chronic histologic damage, treatments, and outcomes","volume":"9","author":"Yandian","year":"2024","journal-title":"Kidney Int Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/nu11040826","article-title":"Effect of red, processed, and white meat consumption on the risk of gastric cancer: an overall and dose(\u2212)response meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Nutrients"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ibd.21468","article-title":"Renal manifestations and complications of inflammatory bowel disease","volume":"17","author":"Oikonomou","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1097\/MIB.0b013e31828a661e","article-title":"Frequency and risk factors of renal insufficiency in inflammatory bowel disease inpatients","volume":"19","author":"Lewis","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.cgh.2020.09.049","article-title":"Risk of urolithiasis in patients with inflammatory bowel disease: a nationwide Danish cohort study 1977-2018","volume":"19","author":"Dimke","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e33938","DOI":"10.1097\/MD.0000000000033938","article-title":"Urolithiasis in patients with inflammatory bowel disease: a systematic review and meta-analysis of 13, 339, 065 individuals","volume":"102","author":"Abdulrhman","year":"2023","journal-title":"Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12894-023-01332-4","article-title":"Causal effects of inflammatory bowel diseases on the risk of kidney stone disease: a two-sample bidirectional mendelian randomization","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Urol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1572-0241.1998.156_b.x","article-title":"Renal and urologic complications of inflammatory bowel disease","volume":"93","author":"Pardi","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.rdc.2018.06.007","article-title":"Renal manifestations of inflammatory bowel disease","volume":"44","author":"Ambruzs","year":"2018","journal-title":"Rheum Dis Clin N Am"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MNH.0000000000000518","article-title":"Enteric hyperoxaluria: role of microbiota and antibiotics","volume":"28","author":"Liu","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/ibd\/izac140","article-title":"Renal and urological disorders associated with inflammatory bowel disease","volume":"29","author":"Kumar","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3390\/nu14081646","article-title":"Dietary management of chronic kidney disease and secondary hyperoxaluria in patients with short bowel syndrome and type 3 intestinal failure","volume":"14","author":"Adler","year":"2022","journal-title":"Nutrients"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/j.crohns.2013.05.001","article-title":"Renal insufficiency in IBD \u2014 prevalence and possible pathogenetic aspects","volume":"7","author":"Primas","year":"2013","journal-title":"J Crohns Colitis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40001-023-01128-0","article-title":"Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample mendelian randomization study","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11255-020-02649-x","article-title":"Urolithiasis in complicated inflammatory bowel disease: a comprehensive analysis of urine profile and stone composition","volume":"53","author":"Torricelli","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40001-022-00687-y","article-title":"5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review","volume":"27","author":"Moss","year":"2022","journal-title":"Eur J Med Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4260365","DOI":"10.1155\/2016\/4260365","article-title":"Interstitial nephritis in a patient with inflammatory bowel disease","volume":"2016","author":"Vasanth","year":"2016","journal-title":"Case Rep Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1620\/tjem.245.149","article-title":"Infliximab-induced tubulointerstitial nephritis with image findings of striated nephrogram in Crohn\u2019s disease","volume":"245","author":"Sato","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/00365521.2024.2345383","article-title":"Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review","volume":"59","author":"Forss","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5858\/arpa.2012-0224-CR","article-title":"Granulomatous interstitial nephritis as a manifestation of Crohn disease","volume":"138","author":"Colvin","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/gast.2002.36613","article-title":"Primary chronic interstitial nephritis in Crohn\u2019s disease","volume":"123","author":"Izzedine","year":"2002","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"103327","DOI":"10.1016\/j.autrev.2023.103327","article-title":"Glomerulonephritis and inflammatory bowel disease: a tale of gut-kidney axis dysfunction","volume":"22","author":"Doumas","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0210-5705(02)70273-2","article-title":"Renal amyloidosis as initial clinical manifestation of Crohn\u2019s disease","volume":"25","author":"Fern\u00e1ndez-Castroagud\u00edn","year":"2002","journal-title":"Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s10620-012-2549-x","article-title":"Inflammatory bowel disease and systemic AA amyloidosis","volume":"58","author":"Sattianayagam","year":"2013","journal-title":"Dig Dis Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjw080","article-title":"Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment","volume":"10","author":"Tosca Cuquerella","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.3748\/wjg.v24.i42.4798","article-title":"Increased end-stage renal disease risk in patients with inflammatory bowel disease: a nationwide population-based study","volume":"24","author":"Park","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.04660513","article-title":"The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease","volume":"9","author":"Ambruzs","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1485087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:37:13Z","timestamp":1727915833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1485087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":40,"alternative-id":["10.3389\/fmed.2024.1485087"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1485087","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"article-number":"1485087"}}